P110 activation protein is strongly expressed in intestinal fibrosis in inflammatory bowel disease patients

Autor: D Lartey, M van Roest, J Verhoeff, J Grootjans, C Buskens, J van der Bilt, M Wildenberg, G D'Haens, M Löwenberg

Publikováno v: Journal of Crohn's and Colitis. 17:i273-i276

Background Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) with limited diagnostic modalities to detect and determine the degree of fibrosis. Fibroblast activation protein alpha (FAP) is a protein with both dipeptidyl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::929e71f448f2dec87bb05b17c7a67b95
https://doi.org/10.1093/ecco-jcc/jjac190.0240

DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib

Autor: M C Dubinsky, G D’Haens, O Dewit, P Juillerat, R Panaccione, T Fujii, A P Lacerda, E Dubcenco, S Anyanwu, C Doshi, M Mallick, A Garrison, J Liu, E V Loftus Jr

Publikováno v: Journal of Crohn's and Colitis. 17:i104-i106

Background Corticosteroids (CS) may be used for induction of remission in Crohn’s disease (CD); however, side effects, toxicities, and low rates of mucosal healing may limit their long-term use. Safety and efficacy of upadacitinib (UPA), an oral se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::89d0d205ac2e0146bba32b6dd0b759bb
https://doi.org/10.1093/ecco-jcc/jjac190.0080

P270 A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease

Autor: D Bettenworth, M E Baker, W Bemelmann, D Bruining, G D’Haens, A D’Hoore, A Dignass, I Dotan, B G Feagan, R Feakins, P Fleshner, J G Fletcher, I Gordon, C Ha, H Gaylyn, V Jairath, C Lu, R Lyu, S C Ng, J Panes, G Rogler, R Mao, J Rimola, W J Sandborn, B Siegmund, M S Silverberg, S Taylor, B Verstockt, F Rieder

Publikováno v: Journal of Crohn's and Colitis. 17:i418-i420

Background Small bowel fibrostenotic strictures are common in patients with Crohn’s disease (CD). No global consensus recommendations on definitions, diagnosis and clinical management are available. Methods Several systematic reviews followed by a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fccc6ad6d832170368b6761072c90c0f
https://doi.org/10.1093/ecco-jcc/jjac190.0400

P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis

Autor: L Peyrin-Biroulet, P Bossuyt, D Bettenworth, E V Loftus Jr., S Anjie, G D’Haens, M Saruta, P Arkkila, D H Kim, D Choi, W Reinisch

Publikováno v: Journal of Crohn's and Colitis. 17:i574-i576

Background Network meta-analysis (NMA) using randomised controlled trial (RCT) data can provide indirect evidence on comparative efficacy of various treatments.1 The NMA reported herein was conducted to evaluate infliximab (IFX) and vedolizumab (VDZ)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30bea3ce999b872696b6241a8ff55d60
https://doi.org/10.1093/ecco-jcc/jjac190.0575

Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases

Autor: Ashwin N Ananthakrishnan, Gilaad G Kaplan, Charles N Bernstein, Kristin E Burke, Paul J Lochhead, Alexa N Sasson, Manasi Agrawal, Jimmy Ho Tuan Tiong, Joshua Steinberg, Wolfgang Kruis, Flavio Steinwurz, Vineet Ahuja, Siew C Ng, David T Rubin, Jean-Frederic Colombel, Richard Gearry, M Abreu, V Ahuja, M Allez, A Ananthakrishnan, W Bemelman, C Bernstein, J Braun, Y Chowers, J-F Colombel, S Danese, G D'Haens, A D'Hoore, A Dignass, I Dotan, M Dubinsky, A Ekbom, P Fleshner, C Gasche, MA Gassull, R Gearry, S Ghosh, P Gibson, A Griffiths, J Halfvarson, S Hanauer, N Harpaz, A Hart, T Hibi, M Kamm, G Kaplan, A Kaser, B Korelitz, P Kotze, I Koutroubakis, W Kruis, P Lakatos, J Lewis, J Lindsay, E Loftus, E Louis, M Lukas, F Magro, U Mahadevan, G Mantzaris, J-Y Mary, D McGovern, B Moum, P Munkholm, M Neurath, S Ng, C O'Morain, T Oresland, R Panaccione, J Panes, Y Panis, J Pemberton, L Peyrin-Biroulet, C Prantera, D Rachmilewitz, Z Ran, W Reinisch, F Remzi, J Rhodes, R Riddell, G Rogler, D Rubin, D Sachar, W Sandborn, B Sands, B Sartor, J Schoelmerich, S Schreiber, C Siegel, B Siegmund, M Silverberg, J Söderholm, A Sood, A Spinelli, E Stange, F Steinwurz, S Targan, S Travis, D Turner, C Tysk, M Vatn, S Vermeire, M Watanabe, T Yamamoto, J Yamamoto-Furusho

Publikováno v: Ananthakrishnan, A N, Kaplan, G G, Bernstein, C N, Burke, K E, Lochhead, P J, Sasson, A N, Agrawal, M, Tiong, J H T, Steinberg, J, Kruis, W, Steinwurz, F, Ahuja, V, Ng, S C, Rubin, D T, Colombel, J-F, Gearry, R & International Organization for Study of Inflammatory Bowel Diseases 2022, ' Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases : an International Organization for Study of Inflammatory Bowel Diseases consensus ', The Lancet Gastroenterology & Hepatology, vol. 7, no. 7, pp. 666-678 . https://doi.org/10.1016/S2468-1253(22)00021-8

Environmental and lifestyle factors play an important role in the natural history of Crohn's disease and ulcerative colitis. A group of international experts from the International Organization for the Study of Inflammatory Bowel Diseases voted on a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f58298ce6a08ab88218f15d73ca467
https://doi.org/10.1016/s2468-1253(22)00021-8